Published online before print December 10, 2007, doi: 10.1161/CIRCULATIONAHA.107.738559
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:85-92.)
© 2008 American Heart Association, Inc.
Pediatric Cardiology |
Long-Term Survival, Modes of Death, and Predictors of Mortality in Patients With Fontan Surgery
From the Boston Adult Congenital Heart Service, Brigham and Women’s Hospital, Beth Israel Deaconess Medical Center, and Children’s Hospital Boston, Harvard Medical School, Boston, Mass.
Correspondence to Dr Paul Khairy, Adult Congenital Heart Center, Montreal Heart Institute, 5000 Bélanger St, Montreal, Quebec, Canada H1T 1C8 (E-mail paul.khairy{at}cardio.CHBoston.org). Reprint requests to Dr Michael J. Landzberg, Director, Boston Adult Congenital Heart Service, Department of Cardiology, Children’s Hospital Boston, 300 Longwood Ave, Boston, MA 02115 (E-mail michael.landzberg@cardio.CHBoston.org).
Received September 4, 2007; accepted October 22, 2007.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— To better define determinants of mortality in patients with univentricular physiology, a database registry was created of patients born in 1985 or earlier with Fontan surgery who were followed up at Children’s Hospital Boston.
Methods and Results— A total of 261 patients, 121 of whom (46.4%) were women, had a first Fontan surgery at a median age of 7.9 years: right atrium–to–pulmonary artery connection in 135 (51.7%); right atrium to right ventricle in 25 (9.6%); and total cavopulmonary connection in 101 (38.7%). Over a median of 12.2 years, 76 (29.1%) died, 5 (1.9%) had cardiac transplantation, 5 (1.9%) had Fontan revision, and 21 (8.0%) had Fontan conversion. Perioperative mortality decreased steadily over time and accounted for 68.4% of all deaths. In early survivors, actuarial freedom from death or transplantation was 93.7%, 89.9%, 87.3%, and 82.6% at 5, 10, 15, and 20 years, respectively, with no significant difference between right atrium to pulmonary artery versus total cavopulmonary connection. Late deaths were classified as sudden in 7 patients (9.2%), thromboembolic in 6 (7.9%), heart failure–related in 5 (6.7%), sepsis in 2 (2.6%), and other in 4 (5.2%). Most sudden deaths were of presumed arrhythmic origin with no identifiable predictor. Independent risk factors for thromboembolic death were lack of antiplatelet or anticoagulant therapy (hazard ratio [HR], 91.6; P=0.0041) and clinically diagnosed intracardiac thrombus (HR, 22.7; P=0.0002). Independent predictors of heart failure death were protein-losing enteropathy (HR, 7.1; P=0.0043), single morphologically right ventricle (HR, 10.5; P=0.0429), and higher right atrial pressure (HR, 1.3 per 1 mm Hg; P=0.0016).
Conclusion— In perioperative survivors of Fontan surgery, gradual attrition occurs predominantly from thromboembolic, heart failure–related, and sudden deaths.
Key Words: death, sudden • Fontan procedure • heart failure • mortality • survival • thrombosis
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The univentricular heart encompasses a spectrum of rare and complex congenital cardiac malformations predominantly managed by a staged surgical approach in view of an ultimate Fontan procedure.1 Initially developed in 1971 with the objective of diverting systemic venous return to the pulmonary artery (PA),2 the Fontan procedure has undergone multiple modifications.3,4 Several case series have reported surgical mortality rates associated with various approaches.5–13 Valuable data on longer-term actuarial survival are likewise emerging, with a focus on particular surgical techniques12,14,15 or congenital diagnoses.16 Causes and distribution of deaths remain poorly defined. As the first cohort of patients with Fontan palliation survive into adulthood and reach middle age, it is becoming increasingly important to define modes of death and to elucidate risk factors for them. Therefore, we assessed long-term survival, modes of death, and predictors of mortality in a large single-center cohort of patients with diverse forms of Fontan palliation.
Editorial p 13
Clinical Perspective p 92
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patient Identification
All patients having undergone Fontan surgery and follow-up at Children’s Hospital Boston were included if they were born before January 1, 1985, and lived within the New England area. Patients with an interrupted inferior vena cava and azygos extension to a superior vena cava who underwent only a bidirectional cavopulmonary shunt were excluded, as were those with surgery limited to a superior vena cava to pulmonary anastomosis (bidirectional or unidirectional cavopulmonary shunt). Patients with a Fontan procedure between April 1973 and July 1991 were identified by a search of an institutional database containing the first 500 consecutive Fontan surgeries.17 Patients with later Fontan procedures were identified by a search of databases from the Departments of Cardiac Surgery and Cardiology. The study was conducted in accordance with institutional Human Subjects Committee guidelines and was approved by the Institutional Review Board.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Clinical Variables and Follow-Up
The database was supplemented by a detailed retrospective review of medical records, preoperative echocardiographic and cardiac catheterization data, operative notes, and an extensive collection of postoperative clinical variables derived from diagnostic tests, interventions, functional status, long-term complications, and mortality on follow-up. Atrioventricular valve anatomy and systemic ventricular morphology were categorized in accordance with previously defined nomenclature18 on the basis of findings from preoperative studies and surgical observations. Type of Fontan surgery was classified into the following 4 categories: right atrium (RA)–to–PA anastomosis; RA–to–right ventricle (RV) connection; intraatrial lateral tunnel (LT); and extracardiac conduit (ECC). The latter 2 were considered subtypes of total cavopulmonary connections. In all cases, surgery involved separation of systemic and pulmonary venous return by excluding the systemic venous return from the systemic ventricle, with or without a residual atrial communication or baffle fenestration. Fontan fenestration, concomitant arrhythmia ablation, and attendant surgery for associated anomalies were recorded as separate variables.
Mode of Death
Original source material was reviewed for all fatalities. Death was considered perioperative if it occurred within 30 days of surgery or before hospital discharge19 and was subclassified as early (ie, within 30 days) or late (ie, after 30 days but during the same hospitalization). Death was labeled secondary to heart failure if it complicated worsening heart failure, as defined by evidence of at least one of the following: orthopnea, nocturnal dyspnea, pulmonary edema, increasing peripheral edema, renal hypoperfusion (ie, worsening renal function), or radiological signs of congestive heart failure.20 Sudden death was defined as death occurring within 1 hour of acute symptoms.21 Death was considered thromboembolic in nature if deemed secondary to thrombus identified either clinically or posthumously within the systemic venous or PA circulation. The site of thromboembolism was further classified into 
1 of the following locations: RA/Fontan, superior vena cava, inferior vena cava, systemic venous atrium, or PA. Death was attributed to sepsis if preceded by documented bacteremia in the setting of clinical symptoms such as fever, chills, malaise, hypotension, and/or mental status changes.22 Remaining deaths were classified as "other" and qualified as "unknown" if the cause of death could not be accurately surmised. The diagnosis of protein-losing enteropathy required the following 2 criteria: hypoalbuminemia (<3.0 mg/dL) for >3 months in the absence of liver or renal disease and accompanying ascites, pleural effusion, edema, diarrhea, or abdominal pain for >3 months.23
Statistical Analysis
Continuous variables are summarized by mean±SD or median and interquartile range (IQR; 25th to 75th percentiles), depending on normality of distribution. Categorical variables are represented by frequencies and percentages. Baseline comparisons between patients with different types of Fontan were performed by Kruskal-Wallis or 
2 tests when appropriate. Predictors of perioperative mortality were explored in univariate and multivariate logistic regression analyses from which odds ratios and 95% confidence intervals were generated. Variables that were significant at the 0.1 level in univariate analyses were included in a stepwise multivariate logistic regression model.
Survival free from transplantation according to type of Fontan was plotted using the Kaplan-Meier method and compared by log-rank statistics in all patients and in the subgroup of perioperative survivors. Time 0 was defined as time of Fontan surgery, after which patient-years were accrued until death or cardiac transplantation. Censoring occurred at the last follow-up visit, on takedown of the Fontan circulation, or at the time of Fontan conversion. In the last case, time 0 was reset to reflect the change in Fontan categorization. Thus, patient-years were attributed to the Fontan category under observation. In a secondary analysis, an intention-to-treat approach was conducted according to the initial type of Fontan without censoring at the time of conversion or resetting time 0.
Cumulative hazards by mode of death were plotted on a linear scale using the product-limit technique. To assess predictors of death or transplantation in longitudinal analyses, univariate and stepwise multivariate Cox proportional-hazard models were used. Demographic, anatomic, surgical, hemodynamic, and clinical (eg, arrhythmias, thromboemboli, and medical therapy) variables were considered. Proportional-hazards assumptions were verified by assessing time-dependent covariates (with time modeled linearly and logarithmically) and by plotting Schoenfeld residuals supplemented by testing for nonzero slopes and Spearman correlation coefficients with time. Two-tailed values of P<0.05 were considered statistically significant. Analyses were performed with SAS software version 9.1 (SAS Institute, Cary, NC).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Baseline Characteristics
A total of 261 patients, 121 female (46.4%), had their first Fontan surgery at a median age of 7.9 years (IQR, 1.1 to 17.5 years), 33 (12.6%) of which were fenestrated. Type of first Fontan was as follows: RA-PA connection in 135 (51.7%), RA-RV in 25 (9.6%), LT in 98 (37.5%), and ECC in 3 (1.1%). Twelve of the 25 (48.0%) RA-RV Fontan procedures were valved. Table 1 summarizes baseline characteristics in all patients and by type of Fontan.
|
Mode of Death
Over a median follow-up of 12.2 years (IRQ, 1.1 to 17.5 years), 76 patients (29.1%) died, 5 (1.9%) had cardiac transplantation, 5 (1.9%) had Fontan revision, and 21 (8.0%) had Fontan conversion to an LT in 16 or ECC in 5. Figure 1 provides an overview of the patient population. Overall, 52 deaths (68.4%) were perioperative; 7 (9.2%) were sudden, 6 (7.9%) were thromboembolic, 5 (6.6%) were due to heart failure, 2 (2.6%) were secondary to sepsis, and 4 (5.3%) were classified as "other." The last category included aortic rupture not qualifying as sudden death in a 17-year-old male patient with an LT Fontan, periprocedural demise in the catheterization laboratory in a 24-year-old woman after fenestration closure of a converted LT Fontan, and 2 deaths of unknown cause.
|
Perioperative Mortality
Of 52 perioperative deaths, 41 (78.9%) were early and 11 (21.1%) were late. All perioperative deaths complicated cardiac surgery: 49 (94.2%) after Fontan palliation and 3 (5.8%) other surgeries. Perioperative Fontan deaths were early in 39 patients (35 initial Fontan, 3 conversion, 1 revision) and late in 10 (9 initial Fontan, 1 revision). The crude perioperative mortality rate for initial Fontan surgery was 16.9% (44 of 261), subcategorized as follows: RA-PA, 27.4% (37 of 135); RA-RV, 0% (0 of 25); LT, 7.1% (7 of 98); and ECC, 0% (0/3). Two of 7 and 3 of 21 patients with Fontan revision and conversion, respectively, died perioperatively. Importantly, perioperative mortality rates decreased steadily over time, from 36.7% (18 of 49) for a first Fontan surgery performed before 1982 to 15.7% (25 of 159) from 1982 to 1989 and 1.9% (1 of 53) in 1990 or later. Independent predictors of perioperative mortality were early surgical era (odds ratio, 3.5 for surgery before 1982; 95% confidence interval, 1.7 to 7.5; P=0.0011), hypoplastic left heart syndrome (odds ratio, 15.2; 95% confidence interval, 4.0 to 57.5; P<0.0001), and RA-PA connection (odds ratio, 3.9; 95% confidence interval, 1.8 to 8.4; P=0.0005).
Long-Term Survival
Freedom from death or cardiac transplantation according to type of Fontan is depicted in Figure 2. In Fontan survivors, the mean age at last follow-up was 25.1±9.8 years. Considering all patients, actuarial event-free survival rates at 1, 5, 10, 15, 20, and 25 years were 80.1%, 77.5%, 74.8%, 72.2%, 68.3%, and 53.6%, respectively, with significant disparities between the various Fontan categories (Figure 2A). Differences were accounted for predominantly by perioperative deaths in an earlier surgical era. In perioperative survivors, freedom from death or cardiac transplantation was comparable among all types of Fontan (Figure 2B). Similarly, long-term cardiac transplantation–free survival was no different in patients with RA-PA versus total cavopulmonary connections (LT and ECC) (P=0.4144). In early survivors, overall actuarial freedom from death or cardiac transplantation at 1, 5, 10, 15, 20, and 25 years was 96.9%, 93.7%, 89.9%, 87.3%, 82.6%, and 69.6%, respectively. Univariate and independent predictors of all-cause mortality or cardiac transplantation are summarized in Table 2.
|
|
In an intention-to-treat approach that did not censor at the time of Fontan conversion or change the Fontan category, actuarial event-free survival rates at 1, 5, 10, 15, 20, and 25 years were 80.5%, 77.7%, 74.4%, 71.8%, 65.0%, and 57.4%, respectively. Overall freedom from death or cardiac transplantation in early survivors was 97.5%, 95.0%, 91.7%, 88.8%, 82.3%, and 70.7% at 1, 5, 10, 15, 20, and 25 years, respectively. Actuarial freedom from death or transplantation according to type of initial Fontan is depicted in Figure 2C and 2D.
Predictors of Mortality by Mode of Death
Cumulative hazards according to mode of death are plotted in Figure 3. For sudden death, a steep rise in cumulative hazard was noted over the first 5 to 10 years after Fontan surgery. In contrast, the hazard for heart failure–related death was minimal initially and increased progressively after 5 to 10 years. The cumulative hazard for thromboembolic death increased steadily 15 years after Fontan surgery.
|
Death resulting from thromboembolism occurred at a median age of 24.9 years (IQR, 15.8 to 33.9 years), 8.7 years (IQR, 0.1 to 18.5 years) after Fontan surgery. Actuarial freedom from thromboembolic death was 98.7% at 10 years and 90.8% at 25 years. All patients had RA-PA Fontan surgeries except for 1 patient with an LT. In 2 cases, thromboembolism was limited to PA; clot was identified within the RA/Fontan in the remainder. In 1 patient, thrombolysis with recombinant tissue plasminogen activator was unsuccessful, and a second patient died despite attempted thrombectomy. At the last follow-up visit preceding thromboembolic death or a diagnosis of clinical thromboembolism, 28.5% and 22.1% of perioperative survivors received anticoagulation and antiplatelet therapy, respectively. Predictors of thromboembolic death are listed in Table 3.
|
Heart failure–related deaths occurred at a mean age of 22.9±7.6 years, 11.9±4.3 years after Fontan surgery. Actuarial freedom from death caused by heart failure was 99.5% at 10 years and 95.8% at 25 years. Univariate and independent predictors are summarized in Table 4.
|
Sudden death occurred at a median age of 20.2 years (IQR, 11.3 to 25.4 years) in 7 patients—3 with RA-PA, 3 with LT, and 1 with RA-RV Fontan—2.9 years (IQR, 1.8 to 7.0 years) after Fontan surgery. Actuarial freedom from sudden cardiac death was 97.0% at 10 years and 96.3% at 25 years. No independent predictor was identified. Three had permanent pacemakers, and no patient had a history of ventricular arrhythmia or identified thrombus. However, pulmonary embolism was suspected in a 6-year-old boy with an LT Fontan who consulted his primary caregiver for cough, was prescribed a nebulizer, was discharged, and experienced dyspnea shortly before cardiac arrest. Autopsy was not performed. Two patients with sudden death had previously documented intraatrial reentrant tachycardia. A 13-year-old boy with an RA-PA Fontan and intraatrial reentrant tachycardia on quinidine had DC cardioversion days before sudden death at school, heralded by palpitations, chest discomfort, dizziness, and headache. A second patient with an LT Fontan died suddenly at 32 years, 2 weeks after atrioventricular node ablation for recalcitrant atrial tachyarrhythmia. Additionally, a 36-year-old woman with an RA-RV Fontan survived cardiac arrest caused by documented intraatrial reentrant tachycardia with rapid 1:1 conduction but suffered neurological impairment.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Benefits and long-term sequelae associated with Fontan palliation are increasingly appreciated as the first recipients with univentricular physiology enter their fourth decade of follow-up. Fontan physiology has been called paradoxical because systemic venous hypertension is imposed with concomitant PA hypotension.24 This hemodynamic compromise underlies many potential previously described late complications, including arrhythmias, heart failure, thromboemboli, hepatic dysfunction, protein-losing enteropathy, and worsening cyanosis.1 Despite these recognized sources of morbidity, mortality outcomes remain incompletely defined. It was our objective, therefore, to conduct a detailed analysis of actuarial long-term survival, modes of death, and predictors of mortality in patients with diverse forms of Fontan palliation.
To provide data relevant to the adult with Fontan palliation, inclusion criteria were limited to birth before 1985. Considering that many such patients had surgery in an earlier era, it is perhaps not surprising that perioperative mortality was the leading cause of death. Encouragingly, surgical mortality rates decreased steadily over time, with deaths in 1990 or later limited to 1 of 53 initial Fontan procedures. These results are consistent with our broader experience with the first 500 Fontan surgeries at Children’s Hospital Boston7 and perioperative mortality rates reported by other high-volume centers.5,6,25 In addition to early surgical era, we and others noted higher perioperative mortality rates in hypoplastic left heart syndrome.8,26,27 In a crude analysis, Ono et al13 similarly found significantly higher mortality with RA-PA versus total cavopulmonary connection. Although our multivariate analyses controlled for date of surgery and Fontan fenestration, relevant surgical variables not considered include cardiopulmonary bypass time, aortic cross-clamping, and modified ultrafiltration.5,8,28,29
Including patients who died perioperatively, 75% actuarial freedom from death or transplantation was noted at 10 years, comparable to prior reports of 69% at 9 years,11 71% at 10 years,17 70% at 10 years in patients with tricuspid atresia,9 and 75% at 10 years in those with RA-PA connections.13 Our observed 68% transplantation-free survival at 20 years is consistent with the 60% reported in 137 patients with tricuspid atresia.9 We further extended results to 25 years, with 54% actuarial transplantation-free survival.
In perioperative survivors, 90% freedom from all-cause death or transplantation was observed at 10 years, 83% at 20 years, and 70% at 25 years. Of the independent risk factors for mortality or transplantation, diuretic therapy is likely a surrogate marker for heart failure, as evidenced by strong correlations with digoxin (
=0.57, P<0.0001) and angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist (=0.56, P<0.0001) therapy. Protein-losing enteropathy is a recognized marker of poor outcome.23,30 Previously identified risk factors for protein-losing enteropathy include longer cardiopulmonary bypass time and morphological RV anatomy.23 With generalized edema, the 5-year survival rate approximates 50%.30 In support of our finding of higher risk associated with hypoplastic left heart syndrome, some7,27,31,32 but not all8 studies have noted increased late mortality with single RV morphology. Cetta et al6 similarly reported higher mortality in patients with elevated postoperative RA pressure and those on daily diuretics.
We further scrutinized the distribution of mode of death, analyzed time-dependent patterns, and assessed risk factors for each subtype. In perioperative survivors, the 3 most common modes of death were thromboembolic, heart failure–related, and sudden. Thromboembolic complications are a well-recognized source of morbidity,33–35 and asymptomatic pulmonary emboli frequently are found.36 Multiple clotting factor abnormalities have been reported, including decreased levels of protein C, protein S, and antithrombin III.37 Increased platelet reactivity also has been recognized.38 Nevertheless, thromboemboli have not previously been linked to mortality in patients with Fontan surgery. We found a sharp increase in risk for thromboembolic death 15 years after Fontan surgery, with 90.8% actuarial event-free survival at 25 years. The presence of recognized clot independently predicted this outcome.
Clinically, the literature is fraught with controversy around prophylactic antiplatelet and/or anticoagulation therapy,1 with some retrospective reviews supporting antiplatelet therapy,39 others suggesting that anticoagulants are more effective,34,40 and still others discouraging routine anticoagulation.41 We found the absence of aspirin or warfarin therapy to be a powerful independent predictor of mortality from thromboembolism. Our own institutional practice, initiated in 1990, was to administer antiplatelet therapy before discharge after Fontan surgery, with the duration at the treating physician’s discretion. No formal departmental policy was implemented for anticoagulation therapy, although standard indications were generally respected.
Interestingly, independent risk factors for death caused by heart failure were similar to predictors of all-cause mortality or transplantation: protein-losing enteropathy, increased RA pressure on follow-up, and single RV morphology. Although no comparable studies on long-term mortality are available, a prior report noted lower peak oxygen uptake consumption on exercise testing in patients with RV morphology.42 We found risk of death from heart failure to be minimal the first 10 years, with 99.5% actuarial event-free survival. The incidence increased thereafter, with 95.8% freedom from heart failure mortality at 25 years.
The incidence of sudden death in patients with Fontan surgery had not previously been defined.43 Here, we report a small but steady decline in freedom from sudden death, with actuarial event-free survival of 96.3% at 25 years. This corresponds to an average annualized incidence of 0.15%, which is similar to reported rates in tetralogy of Fallot and aortic coarctation but lower than complete transposition of the great arteries with an atrial level repair and aortic stenosis.43 Although the cause of sudden death is likely multifactorial, arrhythmias clearly are responsible for a subset of events as evidenced by documented intra-atrial reentrant tachycardia with rapid 1:1 conduction, leading to cardiac arrest. Atrial tachyarrhythmias are highly prevalent, dependent on type of surgery, and are associated with substantial morbidity.44
Study Limitations
To maximize the accuracy of outcome ascertainment and comprehensiveness of the data set, the study population was deliberately limited to patients operated on and followed up at Children’s Hospital Boston. This resulted in the inclusion of <50% of patients having undergone Fontan surgery at our institution. The observed actuarial 10-year survival of 74.8%, however, is comparable to 71.4% in the first 500 consecutive patients,17 suggesting that the study population is reasonably representative of the target population with respect to overall mortality. Definitions for each mode of death were elaborated and applied to the entire cohort for uniformity of classification. Nevertheless, mode of death could not be reliably classified for 2 of 76 events (2.6%). Finally, few patients had ECCs, limiting the interpretation of mortality rates for this specific Fontan subtype.
Conclusions
In this large single-center cohort of patients with various forms of Fontan surgery, the leading cause of death was perioperative, particularly in an earlier era. Gradual attrition was noted thereafter, predominantly from thromboembolic, heart failure–related, and sudden deaths, with 70% actuarial freedom from all-cause death or cardiac transplantation at 25 years. Risk of death from thromboembolism increased 15 years after Fontan surgery and was predicted by clinically identified thrombus and lack of aspirin or warfarin therapy. Heart failure–related mortality was minimal the first 10 years. Independent risk factors were single RV morphology, higher postoperative RA pressure, and protein-losing enteropathy. The incidence of sudden death was 0.15% per year, with most events of presumed arrhythmic origin.
|
Acknowledgments |
|---|
Source of Funding
The study was supported in part by a Canada Research Chair in Adult Congenital Heart Disease and Electrophysiology (Dr Khairy) and the Dunlevie Foundation.
Disclosures
None.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Khairy P, Poirier NC, Mercier LA. Univentricular heart. Circulation. 2007; 115: 800–812.
2. Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971; 26: 240–258.
3. de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations: experimental studies and early clinical experience. J Thorac Cardiovasc Surg. 1988; 96: 682–695.[Abstract]
4. Marcelletti C, Corno A, Giannico S, Marino B. Inferior vena cava-pulmonary artery extracardiac conduit: a new form of right heart bypass. J Thorac Cardiovasc Surg. 1990; 100: 228–232.[Abstract]
5. Knott-Craig CJ, Danielson GK, Schaff HV, Puga FJ, Weaver AL, Driscoll DD. The modified Fontan operation: an analysis of risk factors for early postoperative death or takedown in 702 consecutive patients from one institution. J Thorac Cardiovasc Surg. 1995; 109: 1237–1243.
6. Cetta F, Feldt RH, O’Leary PW, Mair DD, Warnes CA, Driscoll DJ, Hagler DJ, Porter CJ, Offord KP, Schaff HV, Puga FJ, Danielson GK. Improved early morbidity and mortality after Fontan operation: the Mayo Clinic experience, 1987 to 1992. J Am Coll Cardiol. 1996; 28: 480–486.[Abstract]
7. Gentles TL, Mayer JE Jr, Gauvreau K, Newburger JW, Lock JE, Kupferschmid JP, Burnett J, Jonas RA, Castaneda AR, Wernovsky G. Fontan operation in five hundred consecutive patients: factors influencing early and late outcome. J Thorac Cardiovasc Surg. 1997; 114: 376–391.
8. Gaynor JW, Bridges ND, Cohen MI, Mahle WT, Decampli WM, Steven JM, Nicolson SC, Spray TL. Predictors of outcome after the Fontan operation: is hypoplastic left heart syndrome still a risk factor? J Thorac Cardiovasc Surg. 2002; 123: 237–245.
9. Sittiwangkul R, Azakie A, Van Arsdell GS, Williams WG, McCrindle BW. Outcomes of tricuspid atresia in the Fontan era. Ann Thorac Surg. 2004; 77: 889–894.
10. Alphonso N, Baghai M, Sundar P, Tulloh R, Austin C, Anderson D. Intermediate-term outcome following the Fontan operation: a survival, functional and risk-factor analysis. Eur J Cardiothorac Surg. 2005; 28: 529–535.
11. Mitchell ME, Ittenbach RF, Gaynor JW, Wernovsky G, Nicolson S, Spray TL. Intermediate outcomes after the Fontan procedure in the current era. J Thorac Cardiovasc Surg. 2006; 131: 172–180.
12. Giannico S, Hammad F, Amodeo A, Michielon G, Drago F, Turchetta A, Di Donato R, Sanders SP. Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006; 47: 2065–2073.
13. Ono M, Boethig D, Goerler H, Lange M, Westhoff-Bleck M, Breymann T. Clinical outcome of patients 20 years after Fontan operation: effect of fenestration on late morbidity. Eur J Cardiothorac Surg. 2006; 30: 923–929.
14. Petrossian E, Reddy VM, Collins KK, Culbertson CB, MacDonald MJ, Lamberti JJ, Reinhartz O, Mainwaring RD, Francis PD, Malhotra SP, Gremmels DB, Suleman S, Hanley FL. The extracardiac conduit Fontan operation using minimal approach extracorporeal circulation: early and midterm outcomes. J Thorac Cardiovasc Surg. 2006; 132: 1054–1063.
15. Friesen CL, Sherwood MC, Gauvreau K, Frank DF, del Nido PJ, Jonas RA, Mayer JE Jr, Forbess JM. Intermediate outcomes of atrioventricular valvuloplasty in lateral tunnel Fontan patients. J Heart Valve Dis. 2004; 13: 962–971.[Medline] [Order article via Infotrieve]
16. Mastalir ET, Kalil RA, Horowitz ES, Wender O, Sant’Anna JR, Prates PR, Nesralla IA. Late clinical outcomes of the Fontan operation in patients with tricuspid atresia. Arq Bras Cardiol. 2002; 79: 56–60.[Medline] [Order article via Infotrieve]
17. Mayer JE Jr. Late outcome after the Fontan procedure. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 1998; 1: 5–8.[Medline] [Order article via Infotrieve]
18. Jacobs ML, Mayer JE Jr. Congenital Heart Surgery Nomenclature and Database Project: single ventricle. Ann Thorac Surg. 2000; 69: S197–S204.
19. Bartz PJ, Driscoll DJ, Dearani JA, Puga FJ, Danielson GK, O’Leary PW, Earing MG, Warnes CA, Hodge DO, Cetta F. Early and late results of the modified Fontan operation for heterotaxy syndrome 30 years of experience in 142 patients. J Am Coll Cardiol. 2006; 48: 2301–2305.
20. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2004; 110: 2180–2183.
21. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001; 345: 1473–1482.
22. Russell JA. Management of sepsis. N Engl J Med. 2006; 355: 1699–1713.
23. Powell AJ, Gauvreau K, Jenkins KJ, Blume ED, Mayer JE, Lock JE. Perioperative risk factors for development of protein-losing enteropathy following a Fontan procedure. Am J Cardiol. 2001; 88: 1206–1209.[CrossRef][Medline] [Order article via Infotrieve]
24. de Leval MR. The Fontan circulation: a challenge to William Harvey? Nat Clin Pract Cardiovasc Med. 2005; 2: 202–208.[CrossRef][Medline] [Order article via Infotrieve]
25. Jacobs ML, Norwood WI Jr. Fontan operation: influence of modifications on morbidity and mortality. Ann Thorac Surg. 1994; 58: 945–951.[Abstract]
26. Farrell PE Jr, Chang AC, Murdison KA, Baffa JM, Norwood WI, Murphy JD. Outcome and assessment after the modified Fontan procedure for hypoplastic left heart syndrome. Circulation. 1992; 85: 116–122.
27. Julsrud PR, Weigel TJ, Van Son JA, Edwards WD, Mair DD, Driscoll DJ, Danielson GK, Puga FJ, Offord KP. Influence of ventricular morphology on outcome after the Fontan procedure. Am J Cardiol. 2000; 86: 319–323.[CrossRef][Medline] [Order article via Infotrieve]
28. Meyer DB, Zamora G, Wernovsky G, Ittenbach RF, Gallagher PR, Tabbutt S, Gruber PJ, Nicolson SC, Gaynor JW, Spray TL. Outcomes of the Fontan procedure using cardiopulmonary bypass with aortic cross-clamping. Ann Thorac Surg. 2006; 82: 1611–1618.
29. Mosca RS, Kulik TJ, Goldberg CS, Vermilion RP, Charpie JR, Crowley DC, Bove EL. Early results of the Fontan procedure in one hundred consecutive patients with hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2000; 119: 1110–1118.
30. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study: PLE study group. J Thorac Cardiovasc Surg. 1998; 115: 1063–1073.
31. McGuirk SP, Winlaw DS, Langley SM, Stumper OF, de Giovanni JV, Wright JG, Brawn WJ, Barron DJ. The impact of ventricular morphology on midterm outcome following completion total cavopulmonary connection. Eur J Cardiothorac Surg. 2003; 24: 37–46.
32. Piran S, Veldtman G, Siu S, Webb GD, Liu PP. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. 2002; 105: 1189–1194.
33. Rosenthal DN, Friedman AH, Kleinman CS, Kopf GS, Rosenfeld LE, Hellenbrand WE. Thromboembolic complications after Fontan operations. Circulation. 1995; 92 (suppl): II-287–II-293.[Medline] [Order article via Infotrieve]
34. Kaulitz R, Ziemer G, Rauch R, Girisch M, Bertram H, Wessel A, Hofbeck M. Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastomosis). J Thorac Cardiovasc Surg. 2005; 129: 569–575.
35. Monagle P, Karl TR. Thromboembolic problems after the Fontan operation. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2002; 5: 36–47.[CrossRef][Medline] [Order article via Infotrieve]
36. Varma C, Warr MR, Hendler AL, Paul NS, Webb GD, Therrien J. Prevalence of "silent" pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol. 2003; 41: 2252–2258.
37. Tomita H, Yamada O, Ohuchi H, Ono Y, Arakaki Y, Yagihara T, Echigo S. Coagulation profile, hepatic function, and hemodynamics following Fontan-type operations. Cardiol Young. 2001; 11: 62–66.[Medline] [Order article via Infotrieve]
38. Ravn HB, Hjortdal VE, Stenbog EV, Emmertsen K, Kromann O, Pedersen J, Sorensen KE. Increased platelet reactivity and significant changes in coagulation markers after cavopulmonary connection. Heart. 2001; 85: 61–65.
39. Barker PC, Nowak C, King K, Mosca RS, Bove EL, Goldberg CS. Risk factors for cerebrovascular events following Fontan palliation in patients with a functional single ventricle. Am J Cardiol. 2005; 96: 587–591.[CrossRef][Medline] [Order article via Infotrieve]
40. Seipelt RG, Franke A, Vazquez-Jimenez JF, Hanrath P, von Bernuth G, Messmer BJ, Muhler EG. Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. Ann Thorac Surg. 2002; 74: 556–562.
41. Mahnke CB, Boyle GJ, Janosky JE, Siewers RD, Pigula FA. Anticoagulation and incidence of late cerebrovascular accidents following the Fontan procedure. Pediatr Cardiol. 2005; 26: 56–61.[CrossRef][Medline] [Order article via Infotrieve]
42. Ohuchi H, Yasuda K, Hasegawa S, Miyazaki A, Takamuro M, Yamada O, Ono Y, Uemura H, Yagihara T, Echigo S. Influence of ventricular morphology on aerobic exercise capacity in patients after the Fontan operation. J Am Coll Cardiol. 2001; 37: 1967–1974.
43. Silka MJ, Hardy BG, Menashe VD, Morris CD. A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998; 32: 245–251.
44. Khairy P, Dore A, Talajic M, Dubuc M, Poirier N, Roy D, Mercier LA. Arrhythmias in adult congenital heart disease. Expert Rev Cardiovasc Ther. 2006; 4: 83–95.[CrossRef][Medline] [Order article via Infotrieve]
|
Footnotes |
|---|
Guest Editor for this article was Robyn J. Barst, MD.
Related Article:
Circulation 2008 117: 1-3.
This article has been cited by other articles:
 |
|
 |
|
  F. G. Lacour-Gayet, C. J. Lanning, S. Stoica, R. Wang, B. A. Rech, S. Goldberg, and R. Shandas An artificial right ventricle for failing fontan: in vitro and computational study. Ann. Thorac. Surg., July 1, 2009; 88(1): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Kerendi, Z. B. Kramer, W. T. Mahle, B. E. Kogon, K. R. Kanter, and P. M. Kirshbom Perioperative risks and outcomes of atrioventricular valve surgery in conjunction with Fontan procedure. Ann. Thorac. Surg., May 1, 2009; 87(5): 1484 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Odegard, D. Zurakowski, J. A. DiNardo, R. A. Castro, F. X. McGowan Jr., E. J. Neufeld, and P. C. Laussen Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 934 - 941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Hsu and G. D. Pearson Heart Failure in Children: Part I: History, Etiology, and Pathophysiology Circ Heart Fail, January 1, 2009; 2(1): 63 - 70. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Khairy and M. J. Landzberg Adult Congenital Heart Disease: Toward Prospective Risk Assessment of a Multisystemic Condition Circulation, May 6, 2008; 117(18): 2311 - 2312. [Full Text] [PDF]
|
|
|
|
|
|
W. M. Gersony Fontan Operation After 3 Decades: What We Have Learned Circulation, January 1, 2008; 117(1): 13 - 15. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||